Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QBS
|
|||
| Former ID |
DNC009883
|
|||
| Drug Name |
MK-1925
|
|||
| Synonyms |
CHEMBL560667; MK-1925; SCHEMBL3540877; BDBM50296579
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21F3N4
|
|||
| Canonical SMILES |
CC1=C(N(N=C1CNC2CCC(C2)F)CCC#N)C3=CC(=CC(=C3)F)F
|
|||
| InChI |
1S/C19H21F3N4/c1-12-18(11-24-17-4-3-14(20)10-17)25-26(6-2-5-23)19(12)13-7-15(21)9-16(22)8-13/h7-9,14,17,24H,2-4,6,10-11H2,1H3/t14-,17+/m1/s1
|
|||
| InChIKey |
LJTOZIFFXNLWEQ-PBHICJAKSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [1] |
| Voltage-gated potassium channel Kv11.1 (KCNH2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Opioid prodynorphin pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| Voltage gated Potassium channels | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | ||||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.